[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353377-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353377-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identifying-epithelial-cell-progression-signatures-ecpss-from-multi-resolution-multi-omics-data-for-translational-clinical-applications-in-lung-adenocarcinoma","Identifying Epithelial-Cell Progression Signatures (ECPSs) from Multi-Resolution Multi-Omics Data for Translational Clinical Applications in Lung Adenocarcinoma","","Dynamic transcriptomic remodeling of epithelial cells represents a critical hallmark of lung adenocarcinoma (LUAD) progression, yet epithelial-cell progression signatures (ECPSs) linked to this process remain incompletely characterized. A multi-resolution multi-omics analysis identified two opposing ECPSs: a Cancer-Promoting Signature (CPS) progressively increased from normal through early- and advanced-stage lesions, while a Cancer-Suppressing Signature (CSS) decreased and both were validated across transcriptomic resolutions. The CPS and CSS showed strong diagnostic and prognostic value in independent cohorts, and their combined use improved patient stratification.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identifying-epithelial-cell-progression-signatures-ecpss-from-multi-resolution-multi-omics-data-for-translational-clinical-applications-in-lung-adenocarcinoma/353377/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identifying-epithelial-cell-progression-signatures-ecpss-from-multi-resolution-multi-omics-data-for-translational-clinical-applications-in-lung-adenocarcinoma/353377.png","ImageObject",300,407,{"name":42,"@type":43},"RuangKosong","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What two ECPSs were identified in the study?","Question",{"text":63,"@type":64},"The study identified two functionally opposing epithelial-cell progression signatures: a Cancer-Promoting Signature (CPS) and a Cancer-Suppressing Signature (CSS).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did CPS and CSS change across LUAD progression stages?",{"text":68,"@type":64},"CPS progressively upregulated from normal to early- and advanced-stage lesions, whereas CSS gradually downregulated across the same progression continuum.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the clinical value of combining CPS and CSS?",{"text":72,"@type":64},"Combining CPS and CSS better stratified LUAD patients into distinct prognostic subgroups, with CPS high–CSS low associated with the worst prognosis and features such as genomic instability and an immunosuppressive tumor microenvironment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353377,1790200542,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nIdentifying Epithelial-Cell Progression Signatures (ECPSs) from Multi-Resolution Multi-Omics Data for Translational Clinical Applications in Lung Adenocarcinoma  \nXueyao Chen†, Tongxin Lv†, Yang Wu, Fangfang Fan, Shaobo Kang, Renjie Dou, Wanmei Zhang, Dongxue Li, Rui Li and Yanyan Ping *  \nAcademic Editor: Prasoon Agarwal  \nReceived: 30 April 2026  \nRevised: 17 July 2026  \nAccepted: 24 July 2026  \nPublished: 29 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China;  \n[2024020530@hrbmu.edu.cn](2024020530@hrbmu.edu.cn) (X.C.); [2019156034@hrbmu.edu.cn](2019156034@hrbmu.edu.cn) (T.L.); [2018156015@hrbmu.edu.cn](2018156015@hrbmu.edu.cn) (Y.W.);  \n[2023020618@hrbmu.edu.cn](2023020618@hrbmu.edu.cn) (F.F.); [2021020504@hrbmu.edu.cn](2021020504@hrbmu.edu.cn) (S.K.); [lazybean2021@163.com](lazybean2021@163.com) (R.D.);  \n[zwmei1998@gmail.com](zwmei1998@gmail.com) (W.Z.); [2023020569@hrbmu.edu.cn](2023020569@hrbmu.edu.cn) (D.L.); [18794244948@163.com](18794244948@163.com) (R.L.)  \n* [Correspondence: pingyanyan@hrbmu.edu.cn](Correspondence: pingyanyan@hrbmu.edu.cn)  \n† These authors contributed equally to this work.  \nAbstract  \nDynamic transcriptomic remodeling of epithelial cells represents a critical hallmark of lung adenocarcinoma (LUAD) progression, yet epithelial-cell progression signatures (ECPSs) linked to this process remain incompletely characterized, impeding our understanding of malignant LUAD transformation. Here, we performed a multi-resolution multi-omics study and identified two functionally opposing ECPSs: a Cancer-Promoting Signature (CPS) and a Cancer-Suppressing Signature (CSS) . The CPS was progressively upregulated from normal to early-and advanced-stage lesions, while the CSS was gradually downregulated, and both were validated by multi-resolution transcriptomic data. Both the CPS and CSS demonstrated robust diagnostic value for LUAD, particularly in early-stage detection (median AUC > 0.95) . In seven independent validation cohorts, the CPS and CSS served as robust prognostic risk and protective factors, respectively. Their combination could better stratify LUAD patients into distinct prognostic subgroups, with the CPS high–CSS low subgroup showing the worst prognosis, accompanied by high genomic instability, an immunosuppressive tumor microenvironment, and resistance to chemotherapy. Notably, the CPS and CSS exhibited broad translational value in other epithelium-derived cancers. HMGA1, a key CPS gene, showed epithelium-and advanced-stage-specific high expression, which was significantly associated with poor prognosis, genomic instability, and immune escape. Collectively, our study identifies the CPS and CSS as clinically reliable ECPSs, providing valuable biomarkers for clinical application to LUAD.  \nKeywords: epithelial-cell progression signature; multi-omics analysis; cancer-promoting signature; cancer-suppressing signature; lung adenocarcinoma; clinical application  \n1. Introduction  \nLung adenocarcinoma (LUAD) is a lethal epithelial malignancy that is often diagnosed late, with aggressive progression and therapy resistance [1–4] . This is attributed to inadequate understanding of epithelial malignant transformation dynamics—specifically, the sequential, persistent transcriptional remodeling of epithelial cells throughout LUAD progression. As the cells of origin, epithelial cells undergo characteristic, persistent transcriptional remodeling during LUAD progression, acting as intrinsic drivers of malignancy [5] .  \nThus, deciphering these remodeling patterns and identifying epithelial-cell progression signatures (ECPSs) that reflect this dynamic process are critical to addressing clinical LUAD challenges.  \nSingle-cell RNA sequencing (scRNA-s","cbCaidtJSVeoJ7RY","https://ap.wps.com/l/cbCaidtJSVeoJ7RY","pdf",25466134,23,"English","# Introduction\n## Epithelial malignant transformation dynamics in LUAD\n## Limits of static molecular profiling and the need for sequential ECPSs\n## Single-cell RNA-seq progress and remaining gaps\n# Abstract\n## Identifying opposing ECPSs (CPS and CSS)\n## Diagnostic and prognostic performance\n## Translational relevance and key gene insight","[{\"question\":\"What two ECPSs were identified in the study?\",\"answer\":\"The study identified two functionally opposing epithelial-cell progression signatures: a Cancer-Promoting Signature (CPS) and a Cancer-Suppressing Signature (CSS).\"},{\"question\":\"How did CPS and CSS change across LUAD progression stages?\",\"answer\":\"CPS progressively upregulated from normal to early- and advanced-stage lesions, whereas CSS gradually downregulated across the same progression continuum.\"},{\"question\":\"What is the clinical value of combining CPS and CSS?\",\"answer\":\"Combining CPS and CSS better stratified LUAD patients into distinct prognostic subgroups, with CPS high–CSS low associated with the worst prognosis and features such as genomic instability and an immunosuppressive tumor microenvironment.\"}]","Identifying Epithelial-Cell Progression Signatures (ECPSs) from Multi-Resolution Multi-Omics Data for Translational Clinical Applications in Lung Adenocarcinoma | PDF",1790105001,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/caad6e631add24ffc33ea756d1d70c4b.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c18df50d0e96efada5f92b6c527903c.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86c61bc6ebaa4db20d5baa2f87d59b31.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d58dc4cb09e8c607c92a24c9c1a1becf.webp",980,1385]